Evidence map›Paper›PMID 25024509›Full record

ArticleMediators of inflammation2014

The impact of Staphylococcus aureus-associated molecular patterns on staphylococcal superantigen-induced toxic shock syndrome and pneumonia.

Ashenafi Y Tilahun, Melissa Karau, Alessandro Ballard, Miluka P Gunaratna, Anusa Thapa, Chella S David, Robin Patel, Govindarajan Rajagopalan

Abstract read
In one paragraph

Article in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. IFN-American journal of respiratory cell and molecular biology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Staphylococcal Toxic Shock Syndrome Caused by an Intravaginal Product. A Case Report.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2016
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ashenafi Y TilahunDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-9353-0005
Melissa KarauDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-6021-4033
Alessandro BallardDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-4093-2972
Miluka P GunaratnaDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-2166-1046
Anusa ThapaDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9486-8350
Chella S DavidDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA ; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-6344-4141
Govindarajan RajagopalanDepartment of Immunology, Mayo Clinic, Rochester, MN 55905, USA ; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA ; Department of Immunology and Division of Infectious Diseases, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA.ORCID 0000-0003-2608-8162

Funding

HLA class II transgenic mouse models for S. aureus infections and superantigensR01AI068741 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI RAJAGOPALAN, GOVINDARAJAN · 2007 to 2016
$3.1M
Novel Combination Therapy for Staphylococcus aureus PneumoniaR21AI101172 · NIAID · MAYO CLINIC ROCHESTER · PI RAJAGOPALAN, GOVINDARAJAN · 2012 to 2013
$425k
NIAID NIH HHS AI101172NIAID NIH HHS AI68741NIAID NIH HHS R01 AI068741NIAID NIH HHS R21 AI101172
6 · The paper itself

Abstract

Staphylococcus aureus is capable of causing a spectrum of human illnesses. During serious S. aureus infections, the staphylococcal pathogen-associated molecular patterns (PAMPs) such as peptidoglycan, lipoteichoic acid, and lipoproteins and even intact S. aureus, are believed to act in conjunction with the staphylococcal superantigens (SSAg) to activate the innate and adaptive immune system, respectively, and cause immunopathology. However, recent studies have shown that staphylococcal PAMPs could suppress inflammation by several mechanisms and protect from staphylococcal toxic shock syndrome, a life-threatening systemic disease caused by toxigenic S. aureus. Given the contradictory pro- and anti-inflammatory roles of staphylococcal PAMPs, we examined the effects of S. aureus-derived molecular patterns on immune responses driven by SSAg in vivo using HLA-DR3 and HLA-DQ8 transgenic mice. Our study showed that neither S. aureus-derived peptidoglycans (PGN), lipoteichoic acid (LTA), nor heat-killed Staphylococcus aureus (HKSA) inhibited SSAg-induced T cell proliferation in vitro. They failed to antagonize the immunostimulatory effects of SSAg in vivo as determined by their inability to attenuate systemic cytokine/chemokine response and reduce SSAg-induced T cell expansion. These staphylococcal PAMPs also failed to protect HLA-DR3 as well as HLA-DQ8 transgenic mice from either SSAg-induced toxic shock or pneumonia induced by a SSAg-producing strain of S. aureus.

Indexed as

AnimalsHLA-DQ AntigensHLA-DR3 AntigenLymphocyte ActivationMice, TransgenicPneumoniaShock, SepticStaphylococcus aureusSuperantigensHLA-DQ8 antigenHLA-DQ AntigensHLA-DR3 AntigenSuperantigens

Identifiers

PMID25024509
PMCPMC4082930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.